Gayle R. Dolecek, Senior Vice President, Research & Development, Sucampo Pharmaceuticals, said: ‘We are us to see these data from the Phase 3 results of lubiprostone in this study, 12 weeks Brand Viagra 100.0 mg x 24 www.hotgenericonline.com . Lubiprostone may represent a future treatment strategy for OBD approved approved in this patient population. ‘.

Sucampo Pharmaceuticals, today announced the presentation of results from a Phase 3 study, the application of lubiprostone studied in non-cancer pain patients with opioid-induced bowel dysfunction . These results were the subject of of an oral presentation at Digestive Disease Week 2010 conference in New Orleans, Louisiana, May 2010. – Byron Cryer, who was John C. Vanatta III Professor of Medicine at the University of Texas, Southwestern, an investigator in the study and presented the data at DDW, said: ‘Opioid-induced bowel dysfunction in patients with chronic non-cancer pain. A serious problem is in phase 3 results of the study presented here, some patients relief taken from constipation without a reduction in their pain medication ‘.

1,500,000,000 US dollars Health Partnership well on track eliminate Filariasis 2020.